NBE - Therapeutics
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hochbergerstrasse Technology Parc Basel ...Phone Number
+41 616332230Website
www.nbe-therapeutics.comRevenue
$6.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NBE - Therapeutics
NBE Therapeutics is dedicated to developing best-in-class oncology treatments aimed at increasing survival and improving the quality of life for cancer patients globally. Utilizing their innovative antibody-drug conjugate platform, they focus on creating targeted medicines that can effectively reduce or eradicate solid tumors. The company boasts a robust pipeline of ADC product candidates at various stages of development, reflecting their commitment to advancing cancer care. Their international team is driven by a passion for innovation and excellence in the fight against cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NBE - Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NBE - Therapeutics has new funding data
Check if NBE - Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NBE - Therapeutics launches new products
Click to see if NBE - Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on NBE - Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NBE - Therapeutics
Website visits: Recent activity has been detected on your website
Check out if NBE - Therapeutics is spiking on competitors!
NBE - Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined NBE - Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
NBE - Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NBE - Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NBE - Therapeutics.
NBE - Therapeutics financials insights
Gather financial insights about NBE - Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$3.1M
2016
Series B
$20.6M
2020
Series C
$22M
NBE - Therapeutics Tech Stack
A closer look at the technologies used by NBE - Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Funding
Funding
Funding
NBE - Therapeutics News & Media
Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. read moreBoehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. ImBolstering Cancer Platform, Boehringer Acquires NBE for $1.4B USD
Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors
BASEL, Switzerland, Oct. 26, 2020 /PRNewswire/ -- NBE-Therapeutics, a Swiss-based company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform, today announced that it has commenced first-in-human studies of its...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NBE - Therapeutics
Sign Up For FreeTo access detailed company insights
NBE Therapeutics is dedicated to developing best-in-class oncology treatments aimed at increasing survival and improving the quality of life for cancer patients globally. Utilizing their innovative antibody-drug conjugate platform, they focus on creating targeted medicines that can effectively reduce or eradicate solid tumors. The company boasts a... Read More
